Prices are updated after-hours

Parkinson

Impel NeuroPharma Inc.

IMPL 4 | $0.2411 -77.19% 860K

|

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-77.2% 1y) (0.0% 2d) (10.1% 3d) (0.0% 7d) (-28.63% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 5,762,297
https://impelnp.com
Sec Filling | Patents | n/a employees

(US) Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

parkinson treatment

add to watch list Paper trade email alert is off

ALTERITY THERAPEUTICS LTD

PRNAF | $0.0002 -90.0% 11450.0% 0

|

Health Technology

(0.0% 1d) (0.0% 1m) (-95.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (192.0% volume)
Earnings Calendar:
Market Cap: $ 14,901,366
http://www.pranabio.com
Sec Filling | Patents | n/a employees

(AU) Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

parkinson alzheimer neurodegenerative alzheimer’s

add to watch list Paper trade email alert is off

Sio Gene Therapies Inc

SIOX | $0.478 -20.5% 40K

|

Health Technology

(0.0% 1d) (0.0% 1m) (13.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (84.8% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 35,360,144
http://www.siogtx.com
Sec Filling | Patents | 38 employees

(United Kingdom) Sio Gene Therapies Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in New York, NY.

acquisitions gene therapies parkinson neurological

add to watch list Paper trade email alert is off

Stealth BioTherapeutics Corp.

MITO | $0.32 0.25%

|

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1824.23% volume)
Earnings Calendar:
Market Cap: $ 23,536,789
http://www.stealthbt.com
Sec Filling | Patents | 73 employees

(KY) Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in Newton, MA.

mitochondrial dysfunction parkinson sbt-272 tdp-43

add to watch list Paper trade email alert is off

AbbVie Inc.

ABBV | $166.41 1.06% 0.0% 5.5M

|

Health Technology

(0.0% 1d) (-5.8% 1m) (2.5% 1y) (0.8% 2d) (1.5% 3d) (2.9% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap: $ 294,653,364,441
http://www.abbvie.com
Sec Filling | Patents | 30000 employees

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

cancer hiv autoimmunity hepatitis fibrosis metabolic parkinson neurological

Drugs

Alcohol - Hand Sanitizer (Alcohol)
Androgel (Testosterone)
Creon (Pancrelipase)
Depakote (Divalproex Sodium)
Depakote ER (Divalproex Sodium)
Depakote Sprinkles (Divalproex Sodium)
Duopa (Carbidopa and Levodopa)
Gengraf (Cyclosporine)
Humira (Adalimumab)
Kaletra (Lopinavir and Ritonavir)
K-Tab (Potassium Chloride)
Lupaneta Pack (leuprolide acetate and norethindrone acetate)
Lupron Depot (leuprolide acetate)
Lupron Depot-PED (leuprolide acetate)
Marinol (Dronabinol)
Mavyret (Glecaprevir and Pibrentasvir)
Niaspan (Niacin)
Nimbex (Cisatracurium besylate)
Norvir (Ritonavir)
Oriahnn (Elagolix and Estradiol and Norethisterone)
Orilissa (Elagolix)
Rinvoq (Upadacitinib)
Skyrizi (Risankizumab-rzaa)
Survanta (Beractant)
Synthroid (Levothyroxine Sodium)
Tarka (Trandolapril and Verapamil Hydrochloride)
Tricor (Fenofibrate)
Trilipix (Fenofibric Acid)
Ultane (Sevoflurane)
Venclexta (Venetoclax)
Viekira Pak (Dasabuvir and Ombitasvir and Paritaprevir and Ritonavir)
Zemplar (Paricalcitol)

add to watch list Paper trade email alert is off

Alector, Inc.

ALEC | $5.1 0.2% 0.2% 470K

|

Health Technology

(0.0% 1d) (-18.3% 1m) (-23.5% 1y) (0.0% 2d) (0.0% 3d) (-9.8% 7d) (14.69% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 488,321,221
http://www.alector.com
Sec Filling | Patents | 121 employees

(US) Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

neurodegenerative alzheimer parkinson al002 msa treatment alzheimer’s

add to watch list Paper trade email alert is off

Annexon, Inc.

ANNX | $4.57 2.93% 2.84% 1.2M

|

Health Technology

(0.0% 1d) (-25.1% 1m) (-18.7% 1y) (0.0% 2d) (0.0% 3d) (-20.6% 7d) (-14.17% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 358,146,782
http://www.annexonbio.com
Sec Filling | Patents | 24 employees

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in South San Francisco, CA.

sclerosis eye multiple sclerosis alzheimer parkinson alzheimer’s

add to watch list Paper trade email alert is off

Annovis Bio, Inc.

ANVS | $10.09 2.44% -0.15% 220K

|

Health Technology

(0.0% 1d) (-15.0% 1m) (-36.4% 1y) (2.1% 2d) (2.1% 3d) (-9.3% 7d) (-6.96% volume)
Earnings Calendar:
Market Cap: $ 111,104,007
http://www.annovisbio.com
Sec Filling | Patents | 2 employees

(US) Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

neurodegenerative alzheimer parkinson alzheimer’s

add to watch list Paper trade email alert is off

Alterity Therapeutics Limited

ATHE | $2.04 -4.67% -4.9% 54K

|

Health Technology

(0.0% 1d) (15.3% 1m) (-29.9% 1y) (-4.7% 2d) (1.5% 3d) (-16.7% 7d) (103.15% volume)
Earnings Calendar:
Market Cap: $ 17,809,261
http://www.pranabio.com
Sec Filling | Patents | 12 employees

(AU) Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

neurodegenerative alzheimer parkinson ath434 msa multiple system atroph α-synuclein alzheimer’s

add to watch list Paper trade email alert is off

Anavex Life Sciences Corp.

AVXL | News | $3.8 0.0% 2.1M

|

Health Technology

(0.0% 1d) (-26.0% 1m) (-52.9% 1y) (-7.1% 2d) (-7.1% 3d) (-10.6% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-06
Market Cap: $ 312,027,542
http://www.anavex.com
Sec Filling | Patents | 16 employees

(US) Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

neurodegenerative alzheimer nervous system parkinson treatment alzheimer’s

add to watch list Paper trade email alert is off

Brainstorm Cell Therapeutics Inc.

BCLI A | $0.5384 4.69% 4.48% 1M

|

Health Technology

(0.0% 1d) (10.4% 1m) (-82.6% 1y) (3.9% 2d) (3.9% 3d) (-3.4% 7d) (-6.8% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 36,795,256
http://www.brainstorm-cell.com
Sec Filling | Patents | 32 employees

(US) Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.

sclerosis stem cell spinal cord multiple sclerosis t-cell parkinson bone msa nurown treatment ceiling

add to watch list Paper trade email alert is off

Gain Therapeutics Inc

GANX | $3.155 0.16% 0.16% 71K

|

Professional, Scientific, and T...

(0.0% 1d) (-27.2% 1m) (-41.4% 1y) (0.0% 2d) (0.0% 3d) (2.9% 7d) (-11.52% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 51,173,182
https://www.gaintherapeutics.com
Sec Filling | Patents | 27 employees

Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.

parkinson drug discovery treatment optical

add to watch list Paper trade email alert is off

India Globalization Capital Inc.

IGC 4 | $0.49 2.92% 0.74% 610K

|

Health Technology

(0.0% 1d) (44.1% 1m) (36.1% 1y) (2.1% 2d) (-16.9% 3d) (11.6% 7d) (-54.43% volume)
Earnings Calendar:
Market Cap: $ 31,229,875
http://www.igcinc.us
Sec Filling | Patents | 50 employees

India Globalization Capital, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications such as Alzheimer's disease, Parkinson's disease, and pain. It operates through the Infrastructure Business and Life Sciences segments. The Infrastructure Business segment involves the rental of heavy construction equipment, execution of construction contracts, and purchase and reseal of physical commodities used in infrastructure. The Life Sciences segment includes a biotech component, and a vertically integrated hemp-cannabinoid based healthcare and wellness business, which involves the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

alzheimer parkinson construction alzheimer’s

Drugs

Hyalolex Hand Sanitizer (ALCOHOL)
Hyalolex Hand Sanitizer with Lemon and Zinc (ALCOHOL)

add to watch list Paper trade email alert is off

YUMANITY THERAPEUTICS, INC.

KA A | $0.5196 6.89% 6.45% 480K

|

(0.0% 1d) (-10.5% 1m) (-86.8% 1y) (0.0% 2d) (12.8% 3d) (55.9% 7d) (-33.41% volume)
Earnings Calendar:
Market Cap: $ 5,696,094
https://www.proteostasis.com
Sec Filling | Patents | 45 employees

(US) Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company's most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson's disease. Yumanity's drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity's pipeline consists of additional programs focused on Lewy body dementia, multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.

treatment dementia biopharma com alzheimer's disease parkinson pharma arm drug candidate system ytx-7739 disease cel cov alzheimer's gen drug discovery parkinson's tiona alzheimer als rapid program therapeutics neurodegenerative pot phase 1 potential tempo sclerosis platform rap alzheimer’s

add to watch list Paper trade email alert is off

Micron Technology, Inc.

MU F | $106.71 -4.66% -4.89% 34M

|

Electronic Technology

(0.0% 1d) (-2.8% 1m) (74.7% 1y) (0.0% 2d) (-8.2% 3d) (-12.0% 7d) (32.26% volume)
Earnings Calendar: 2024-03-20
Market Cap: $ 118,167,251,018
http://www.micron.com
Sec Filling | Patents | 40000 employees

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU); Mobile Business Unit (MBU); Storage Business Unit (SBU); and Embedded Business Unit (EBU). The Compute and Networking Business Unit segment includes memory products sold into cloud server, enterprise, client, graphics, and networking markets. The Mobile Business Unit segment offers memory products sold into smartphone, and other mobile-device markets. The Storage Business Unit segment comprises of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer solid-state drive (SSD) markets, other discrete storage products sold in component and wafer forms to the removable storage markets, and sales of 3D XPoint memory. The Embedded Business Unit segment consists of memory and storage products sold into automotive, industrial, and consumer markets. The company was founded by Ward D. Parkinson, Joseph L. Parkinson, Dennis Wilson, and Doug Pitman 0n October 5, 1978 and is headquartered in Boise, ID.

computational parkinson automotive 3d

add to watch list Paper trade email alert is off

NeuroSense Therapeutics Ltd.

NRSN | $1.435 -5.59% -5.92% 120K

|

(0.0% 1d) (-21.5% 1m) (-25.3% 1y) (-6.6% 2d) (-11.3% 3d) (-7.2% 7d) (-54.64% volume)
Earnings Calendar:
Market Cap: $ 22,388,930
https://www.neurosense-tx.com
Sec Filling | Patents | n/a employees

NeuroSense Therapeutics is a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. NeuroSense was founded in 2017 by Alon Ben-Noon, following a chance meeting with Shay Rishoni, an ALS patient. During this meeting, Alon was inspired by Shay, who served as the CEO of a non-profit organization for ALS. Despite Shay not having a physical voice, therefore communicating via eye movement and computer software, the connection was instant. Shay detailed his activities in the ALS field, and described the efforts that are being made to solve the ALS puzzle, leading Alon to team up with world-renowned scientists and colleagues in order to research and develop an effective drug for ALS patients, bringing about the establishment of NeuroSense. To date, the company has commenced with a breakthrough treatment for ALS that will halt, or significantly delay disease progression, as well as developments for Alzheimer’s and Parkinson’s diseases. NeuroSense is focused on creating a combined therapeutic strategy, targeting multiple pertinent mechanisms in these complex diseases. Its research team and advisory board members are multidisciplinary professionals who have many years of experience with drug development and clinical programs, as well as personal connections to neurodegenerative diseases. Their collective expertise and background enable us to move in a fast and efficient manner to achieve its goals. NeuroSense is currently preparing for a phase 2b/3 clinical trial using PrimeC in patients with ALS. NeuroSense is also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. Additionally, NeuroSense is studying the mechanisms of action and relevant biomarkers for these diseases.

israel als treatment profitable communication computational parkinson alzheimer neurodegenerative alzheimer’s ycombinator

add to watch list Paper trade email alert is off

Trevi Therapeutics, Inc.

TRVI | $2.82 5.03% 4.79% 140K

|

Health Technology

(0.0% 1d) (-23.5% 1m) (-5.0% 1y) (5.2% 2d) (9.7% 3d) (0.7% 7d) (-19.29% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 194,467,671
http://www.trevitherapeutics.com
Sec Filling | Patents | 17 employees

Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.

chronic cough fibrosis parkinson neurological treatment

add to watch list Paper trade email alert is off

ACADIA Pharmaceuticals Inc.

ACAD | $16.82 -1.47% -1.49% 3.5M

|

Health Technology

(0.0% 1d) (-8.6% 1m) (-16.3% 1y) (0.0% 2d) (-2.3% 3d) (-0.4% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 2,771,456,983
http://www.acadia-pharm.com
Sec Filling | Patents | 503 employees

(US) ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

nervous system parkinson msa treatment

add to watch list Paper trade email alert is off

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M

|

EGOX | $0.0515 43.06% 30.1% 330M

|

OLB 4 | $0.33 -14.95% 25.53% 840K

|

Technology Services

NVFY | $2.77 31.28% 23.83% 33M

|

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M

|

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M

|

Distribution Services

INSG | $3.03 25.21% 20.13% 330K

|

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K

|

WLGS | $0.59 18.0% 17.9% 2.3M

|

ASNS | $0.828 21.75% 17.86% 18K

|

Last 48 Hours Insiders Buying

RXO P 200000 | $19.37 2.32% 0.0% 1M

|

| 23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M

|

| 22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K

|

Health Technology

| 22:30
BCDA P 2750 | $0.377 -1.4% 97K

|

Health Technology

| 22:00
RMCF | $3.67 3.38% 3.27% 11K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar